Pricing Log in Create free account
Saturday 17 October 2026 Export PBYI’s income statement to Excel — free account

Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Puma Biotechnology, Inc. (PBYI) Business Profile

Updated before January 2025

Company Overview

Puma Biotechnology, Inc. (PBYI) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment of cancer. Founded in 2010 by Alan H. Auerbach, who also serves as the company’s Chairman, Chief Executive Officer, and President, Puma Biotechnology is headquartered in Los Angeles, California. The company’s mission is to improve the lives of cancer patients by developing targeted therapies that address unmet medical needs. Since its inception, Puma Biotechnology has focused on advancing its pipeline of oncology treatments, with a particular emphasis on breast cancer therapies.

The company’s leadership team includes experienced professionals with extensive backgrounds in the pharmaceutical and biotechnology industries. Alan H. Auerbach, the founder, has a proven track record in oncology drug development, having previously served as the founder and CEO of Cougar Biotechnology, which was acquired by Johnson & Johnson. Other key members of the leadership team include Dr. Richard Bryce, Chief Medical and Scientific Officer, and Maximo F. Nougues, Chief Financial Officer, both of whom bring significant expertise in clinical development and financial management, respectively.

Core Business Segments

Puma Biotechnology focuses primarily on the development and commercialization of oncology therapies. The company’s core business segments include:

1. Targeted Cancer Therapies

Puma Biotechnology’s flagship product is NERLYNX® (neratinib), an oral medication approved for the extended adjuvant treatment of HER2-positive early-stage breast cancer. NERLYNX is also being investigated for additional indications, including metastatic breast cancer and other solid tumors. The drug works by irreversibly binding to the HER2 receptor, thereby inhibiting cancer cell growth and proliferation.

2. Clinical Development Programs

In addition to NERLYNX, Puma Biotechnology is actively engaged in clinical trials to expand its product pipeline. The company is exploring the use of neratinib in combination with other therapies to treat various types of cancer, including HER2-mutated non-small cell lung cancer (NSCLC) and HER2-positive gastric cancer. These clinical programs aim to address unmet medical needs and broaden the therapeutic applications of Puma’s products.

3. Licensing and Partnerships

Puma Biotechnology has established licensing agreements with pharmaceutical companies to expand the global reach of its products. For example, the company has partnered with Pierre Fabre to commercialize NERLYNX in Europe and with CANbridge Pharmaceuticals for distribution in China. These partnerships enable Puma to leverage the expertise and resources of its collaborators to maximize the impact of its therapies.

Business Model

Puma Biotechnology operates on a business model centered around the development, approval, and commercialization of targeted cancer therapies. The company generates revenue primarily through the sales of NERLYNX, as well as through licensing agreements and milestone payments from its partners. Puma invests heavily in research and development (R&D) to advance its clinical pipeline and bring new therapies to market.

The company’s approach to integrating products and services involves a strong focus on patient support programs. For instance, Puma offers the NERLYNX Patient Support Program, which provides financial assistance, educational resources, and access to healthcare professionals to ensure that patients can effectively manage their treatment. This patient-centric approach not only enhances the company’s reputation but also fosters long-term customer loyalty.

Strategic Direction

Puma Biotechnology’s strategic direction is guided by its commitment to innovation, patient care, and global expansion. Key elements of the company’s future plans include:

  • Pipeline Expansion: Puma is focused on advancing its clinical development programs to explore new indications for neratinib and identify additional therapeutic candidates.
  • Global Market Penetration: The company aims to strengthen its presence in international markets through strategic partnerships and licensing agreements.
  • Sustainability Goals: While Puma has not explicitly outlined sustainability initiatives, the company is committed to ethical business practices and the responsible development of its therapies.
  • New Product Categories: Puma is exploring opportunities to diversify its product portfolio by investigating combination therapies and novel drug delivery mechanisms.

Competitive Landscape

Puma Biotechnology operates in a highly competitive oncology market, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Roche: A global leader in oncology, Roche offers a range of HER2-targeted therapies, including Herceptin, Perjeta, and Kadcyla.
  • Novartis: Known for its innovative cancer treatments, Novartis markets Kisqali, a CDK4/6 inhibitor for breast cancer.
  • AstraZeneca: AstraZeneca’s oncology portfolio includes Tagrisso and Enhertu, which target specific cancer mutations.
  • Seattle Genetics (Seagen): Seagen specializes in antibody-drug conjugates (ADCs) for cancer treatment.

Puma differentiates itself through its focus on oral therapies and its commitment to addressing unmet medical needs in oncology.

Risk Factors

Puma Biotechnology faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the sales of NERLYNX, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can delay product launches.
  • Supply Chain Disruptions: Puma’s reliance on third-party manufacturers and suppliers exposes it to potential supply chain disruptions.
  • Intellectual Property Risks: The company’s success depends on its ability to protect its intellectual property and defend against patent challenges.

Recent Developments

In recent years, Puma Biotechnology has made significant progress in expanding the indications for NERLYNX. The company has initiated clinical trials to evaluate the drug’s efficacy in treating HER2-mutated NSCLC and other cancers. Additionally, Puma has strengthened its global presence through licensing agreements with partners in Europe, Asia, and Latin America.

The COVID-19 pandemic posed challenges for Puma, including disruptions to clinical trials and supply chains. However, the company has demonstrated resilience by adapting its operations and maintaining a focus on patient care.

Investment Considerations

Investors considering Puma Biotechnology should weigh the following strengths and risks:

Strengths:

  • Established presence in the oncology market with a flagship product, NERLYNX.
  • Strong leadership team with extensive industry experience.
  • Robust clinical pipeline with potential for new indications and therapies.
  • Strategic partnerships that enhance global market access.

Risks:

  • Heavy reliance on a single product for revenue generation.
  • Intense competition in the oncology market.
  • Regulatory and intellectual property challenges.
  • Potential for supply chain disruptions.

Conclusion

Puma Biotechnology, Inc. is a dynamic player in the oncology market, with a strong focus on developing targeted therapies for cancer patients. The company’s flagship product, NERLYNX, has established a solid foundation for growth, and its ongoing clinical programs hold promise for future innovation. While Puma faces challenges such as market dependence and competition, its strategic partnerships and commitment to patient care position it well for long-term success. As the company continues to expand its global footprint and diversify its product portfolio, it remains a compelling option for investors seeking exposure to the biopharmaceutical sector.